Clonazepam disposition in pediatric patients

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Pediatric Neurology

Background:

• Clonazepam (CZP) is an anticonvulsant medication used in epilepsy treatment.
• Understanding CZP pharmacokinetics and metabolism is crucial for optimizing therapeutic outcomes in pediatric patients.

Purpose of the Study:

• To determine the pharmacokinetic profiles of clonazepam (CZP) and its metabolites, 7-aminoclonazepam (7ACZP) and 7-acetamidoclonazepam (7AACZP), in pediatric epilepsy patients.
• To investigate the variability in metabolic rates, specifically CZP nitroreduction and 7ACZP acetylation.

Main Methods:

• Plasma concentrations of CZP and its metabolites were measured in 10 pediatric epilepsy patients (2-18 years) during a single dosing interval.
• Pharmacokinetic parameters, including clearance (CL/F) for CZP nitroreduction and 7ACZP acetylation, were calculated.
• Sensitive analytical methods were used to detect and quantify drug and metabolite concentrations.

Main Results:

• Significant inter-individual variability was observed in CZP nitroreduction rates (CL/F: 7-64 ml/h/kg) and 7ACZP acetylation rates (CL/F: 10-85 ml/h/kg).
• 7-acetamidoclonazepam (7AACZP) was not detected (< 5 ng/ml) using the employed methods.
• No correlation was found between patient age or weight and the observed metabolic rates.

Conclusions:

• Metabolic rates for clonazepam (CZP) and its primary metabolite 7-aminoclonazepam (7ACZP) exhibit substantial variability in pediatric epilepsy patients.
• Genetic control of 7ACZP acetylation is known; further research is needed to explore potential genetic influences on CZP nitroreduction.
• Investigating these metabolic differences may help explain variations in clinical responses to CZP among pediatric patients.